Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 590-596

  Vague, Philippe ^a   Selam, Jean Louis ^b   Skeie, Svein ^c   De Leeuw, Ivo ^d   Elte, Jan W F ^e   Haahr, Hanne ^f   Kristensen, Allan ^f   Draeger, Eberhard ^f  

^a TIMONE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c Hjertelaget Research Foundation   (Norway)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e SINT FRANCISCUS GASTHUIS   (Netherlands)

^f NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; BODY WEIGHT; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRURITUS; RHINITIS; SELF MONITORING; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 1; EATING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0038418746     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.590     Document Type: Article

References (27)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes and the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 45:1289-1298, 1996
3. Reichard O, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment in the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
4. Diabetes Control and Complications Trial Research Group: Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 18:1415-1427, 1995
5. Diabetes Control and Complications Trial Research Group: Hypoglycemia in the diabetes control and complications trial. Diabetes 46:271-286, 1997
6. Diabetes Control and Complications Trial Research Group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90:450-459, 1991
7. Starke A, Heinemann L, Hohlmann A, Berger M: The action profiles of human NPH insulin preparations. Diabet Med 6:239-244, 1989
8. 125I-NPH insulin in diabetic patients. Horm Metab Res 15:274-278, 1983
9. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354:307-335, 1999
10. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639-643, 2000
11. Pieber TR, Eugene-Jolchine I, Derobert E: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes: the European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 23:157-162, 2000
12. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine. Diabetes Care 23:1666-1671, 2000
13. Rosenstock J, Park G, Zimmerman J: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens: U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137-1142, 2000
14. Lindholm E: New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 16:475-492, 2002
15. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731, 1995
16. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrøm J, Hasselager E, Larsen UD, Ribel U, Schäffer L, Vad K, Jonassen I: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39: 281-288, 1996
17. Home P, Lindholm A, Riis A: Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomised controlled trial. Diabet Med 17:762-771, 2000
18. Declaration of Helsinki: Recommendations guiding medical physicians in biomedical research involving human patients. JAMA 277:925-926, 1997
19. Roberts A, Bayer T, Munksgaard E, Lang H, Standl E: Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal/bolus regimen (Abstract). Diabetes 50 (Suppl. 2):A129, 2001
20. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005, 2000
21. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR: Postprandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 17:371-375, 2000
22. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 24:296-301, 2001
23. Strange P, McGill J, Mazzeo M: Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analog (Abstract). Diabetes 48 (Suppl. 1):A103, 1999
24. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
25. Scholtz HE, van Niekerk, Meyer BH, Rosenkranz B: An assessment of the variability in the pharmacodynamics of HOE901 compared to NPH insulin and ultalente human insulins using the euglycaemic clamp technique. Diabetologia 42 (Suppl. 1):A235, 1999
26. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T: Time-action profile of the soluble, fatty acid acylated, long-acting insulin analog NN304. Diabet Med 16:332-338, 1999
27. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52-59, 1990